Literature DB >> 29658779

Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting.

Gregory P Forlenza1, Faye M Cameron2, Trang T Ly3, David Lam4, Daniel P Howsmon2, Nihat Baysal2, Georgia Kulina4, Laurel Messer1, Paula Clinton3, Camilla Levister4, Stephen D Patek5, Carol J Levy4, R Paul Wadwa1, David M Maahs1,3, B Wayne Bequette2, Bruce A Buckingham3.   

Abstract

BACKGROUND: Initial Food and Drug Administration-approved artificial pancreas (AP) systems will be hybrid closed-loop systems that require prandial meal announcements and will not eliminate the burden of premeal insulin dosing. Multiple model probabilistic predictive control (MMPPC) is a fully closed-loop system that uses probabilistic estimation of meals to allow for automated meal detection. In this study, we describe the safety and performance of the MMPPC system with announced and unannounced meals in a supervised hotel setting. RESEARCH DESIGN AND METHODS: The Android phone-based AP system with remote monitoring was tested for 72 h in six adults and four adolescents across three clinical sites with daily exercise and meal challenges involving both three announced (manual bolus by patient) and six unannounced (no bolus by patient) meals. Safety criteria were predefined. Controller aggressiveness was adapted daily based on prior hypoglycemic events.
RESULTS: Mean 24-h continuous glucose monitor (CGM) was 157.4 ± 14.4 mg/dL, with 63.6 ± 9.2% of readings between 70 and 180 mg/dL, 2.9 ± 2.3% of readings <70 mg/dL, and 9.0 ± 3.9% of readings >250 mg/dL. Moderate hyperglycemia was relatively common with 24.6 ± 6.2% of readings between 180 and 250 mg/dL, primarily within 3 h after a meal. Overnight mean CGM was 139.6 ± 27.6 mg/dL, with 77.9 ± 16.4% between 70 and 180 mg/dL, 3.0 ± 4.5% <70 mg/dL, 17.1 ± 14.9% between 180 and 250 mg/dL, and 2.0 ± 4.5%> 250 mg/dL. Postprandial hyperglycemia was more common for unannounced meals compared with announced meals (4-h postmeal CGM 197.8 ± 44.1 vs. 140.6 ± 35.0 mg/dL; P < 0.001). No participants met safety stopping criteria.
CONCLUSIONS: MMPPC was safe in a supervised setting despite meal and exercise challenges. Further studies are needed in a less supervised environment.

Entities:  

Keywords:  Artificial pancreas; Clinical trial; Fully closed-loop; Type 1 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29658779      PMCID: PMC5963546          DOI: 10.1089/dia.2017.0424

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  50 in total

1.  Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.

Authors:  Firas H El-Khatib; Courtney Balliro; Mallory A Hillard; Kendra L Magyar; Laya Ekhlaspour; Manasi Sinha; Debbie Mondesir; Aryan Esmaeili; Celia Hartigan; Michael J Thompson; Samir Malkani; J Paul Lock; David M Harlan; Paula Clinton; Eliana Frank; Darrell M Wilson; Daniel DeSalvo; Lisa Norlander; Trang Ly; Bruce A Buckingham; Jamie Diner; Milana Dezube; Laura A Young; April Goley; M Sue Kirkman; John B Buse; Hui Zheng; Rajendranath R Selagamsetty; Edward R Damiano; Steven J Russell
Journal:  Lancet       Date:  2016-12-20       Impact factor: 79.321

2.  Pathway to artificial pancreas systems revisited: moving downstream.

Authors:  Aaron Kowalski
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

3.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  Inpatient trial of an artificial pancreas based on multiple model probabilistic predictive control with repeated large unannounced meals.

Authors:  Fraser Cameron; Günter Niemeyer; Darrell M Wilson; B Wayne Bequette; Kari S Benassi; Paula Clinton; Bruce A Buckingham
Journal:  Diabetes Technol Ther       Date:  2014-09-26       Impact factor: 6.118

5.  Use of an artificial pancreas among adolescents for a missed snack bolus and an underestimated meal bolus.

Authors:  Daniel R Cherñavvsky; Mark D DeBoer; Patrick Keith-Hynes; Benton Mize; Molly McElwee; Susan Demartini; Spencer F Dunsmore; Christian Wakeman; Boris P Kovatchev; Marc D Breton
Journal:  Pediatr Diabetes       Date:  2014-10-27       Impact factor: 4.866

6.  Physiology-Invariant Meal Detection for Type 1 Diabetes.

Authors:  James Weimer; Sanjian Chen; Amy Peleckis; Michael R Rickels; Insup Lee
Journal:  Diabetes Technol Ther       Date:  2016-10-05       Impact factor: 6.118

7.  Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.

Authors:  P G Jacobs; J El Youssef; R Reddy; N Resalat; D Branigan; J Condon; N Preiser; K Ramsey; M Jones; C Edwards; K Kuehl; J Leitschuh; U Rajhbeharrysingh; J R Castle
Journal:  Diabetes Obes Metab       Date:  2016-08-15       Impact factor: 6.577

8.  Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial Pancreas.

Authors:  Gregory P Forlenza; Bruce Buckingham; David M Maahs
Journal:  J Pediatr       Date:  2015-11-05       Impact factor: 4.406

9.  Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours.

Authors:  Arianne C van Bon; Yoeri M Luijf; Rob Koebrugge; Robin Koops; Joost B L Hoekstra; J Hans DeVries
Journal:  Diabetes Technol Ther       Date:  2013-11-13       Impact factor: 6.118

10.  Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home.

Authors:  H Blauw; A C van Bon; R Koops; J H DeVries
Journal:  Diabetes Obes Metab       Date:  2016-04-25       Impact factor: 6.577

View more
  18 in total

1.  A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm.

Authors:  Laurel H Messer; Cari Berget; Gregory P Forlenza
Journal:  Diabetes Technol Ther       Date:  2019-05-29       Impact factor: 6.118

2.  A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy.

Authors:  Cari Berget; Laurel H Messer; Gregory P Forlenza
Journal:  Diabetes Spectr       Date:  2019-08

Review 3.  Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes.

Authors:  Rozana Ramli; Monika Reddy; Nick Oliver
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

4.  Where Do We Stand with Closed-Loop Systems and Their Challenges?

Authors:  Melanie Jackson; Jessica R Castle
Journal:  Diabetes Technol Ther       Date:  2020-05-22       Impact factor: 6.118

5.  Using an Online Disturbance Rejection and Anticipation System to Reduce Hyperglycemia in a Fully Closed-Loop Artificial Pancreas System.

Authors:  John P Corbett; Jose Garcia-Tirado; Patricio Colmegna; Jenny L Diaz Castaneda; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2021-12-03

Review 6.  Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field.

Authors:  Gregory P Forlenza; Laurel H Messer; Cari Berget; R Paul Wadwa; Kimberly A Driscoll
Journal:  Curr Diab Rep       Date:  2018-09-26       Impact factor: 4.810

Review 7.  Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy.

Authors:  Julia Fuchs; Roman Hovorka
Journal:  Expert Rev Med Devices       Date:  2020-07-03       Impact factor: 3.166

Review 8.  Time in Range for Closed-Loop Systems versus Standard of Care during Physical Exercise in People with Type 1 Diabetes: A Systematic Review and Meta-Analysis.

Authors:  Max L Eckstein; Benjamin Weilguni; Martin Tauschmann; Rebecca T Zimmer; Faisal Aziz; Harald Sourij; Othmar Moser
Journal:  J Clin Med       Date:  2021-05-31       Impact factor: 4.241

9.  Initiating hybrid closed loop: A program evaluation of an educator-led Control-IQ follow-up at a large pediatric clinic.

Authors:  Laurel H Messer; Cari Berget; Ashlee Ernst; Lindsey Towers; Robert H Slover; Gregory P Forlenza
Journal:  Pediatr Diabetes       Date:  2021-03-16       Impact factor: 4.866

Review 10.  [Individualization of diabetes treatment by automated insulin delivery].

Authors:  T Biester; K Dovc; A Chobot; M Tauschmann; T Kapellen
Journal:  Monatsschr Kinderheilkd       Date:  2021-07-13       Impact factor: 0.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.